Skip to content

Twitter page opens in new window Linkedin page opens in new window Instagram page opens in new window

investorenquiries@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

December 23, PharmAust Commences MPL Manufacture for Human Clinical Trials

201223_PAA_Syngene_FightMND_Manufacture

Category: News & Announcements 2020By PharmAust December 23, 2020

Related posts

December 31, Top 20 Shareholders
January 4, 2021

December 22, PharmAust Set to Commence Phase IIb Anticancer Canine Trial
December 22, 2020

December 21, Epichem Awarded DNDi Extension
December 21, 2020

December 4, Issued Capital
December 4, 2020

November 30, Top 20 Shareholders
December 1, 2020

November 5, AGM Results
November 5, 2020

Recent Articles

Notice of General Meeting
May 26, 2023
Motor Neurone Disease Clinical Trial Update
May 22, 2023
Progress update on Phase 1/2 MND interim analysis
May 16, 2023
Independent tests show MPL retains long-term shelf-life
May 10, 2023

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

pharmaust Follow

@ ·

now

Reply on Twitter Retweet on Twitter Like on Twitter Twitter

Load More

Copyright © 2023 PharmAust. All rights reserved.

nil

Website Design & Digital Marketing Perth by Total Click Solutions